Using HRAs Employers that want to avoid covering GLP-1s for weight loss in their general health plans could provide a health reimbursement account (HRA), using pre-tax dollars, to cover a portion of the cost of these medications
Importantly, targeting of MK-801 to GLP-1 receptor-expressing brain regions circumvents adverse physiological and behavioural effects associated with MK-801 monotherapy
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss drugs
Overall, the safety and tolerability profile for oral semaglutide in PIONEER 12 was consistent with the results from the global PIONEER trials and with the general safety profile of the GLP-1RA drug class [27]
This is where the double standard shows up, loudly
Both are prescription-pipeline assets in active development